2015-08-25T17:41:25-05:00 2014-12-31 BDO USA LLP 7101 WISCONSIN AVE SUITE 800 BETHESDA MD 208144827 990 2014-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC % ERIN HULTMAN CPA FINANCE D AMER 5714831300 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 ERIN HULTMAN CPA FINANCE DIRECTOR 7038930600 2015-08-21 true Mike Sorrells P00001737 3016544900 2014 2016-02-25 16:41:14Z ASCO ALLEN LICHTER MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 169709540 false X WWW.ASCO.ORG X 1964 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY PATIENT CARE. 18 18 432 1200 15853104 4115385 8477875 9852055 76312383 83008682 6859928 7150343 1351743 1917561 93001929 101928641 1103926 1900652 0 0 30968009 34296368 0 0 2836985 47687206 51865291 79759141 88062311 13242788 13866330 195594554 217539280 98271504 112809634 97323050 104729646 X ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY CARE. ASCO VISION STATEMENTS: -- ALL CANCER PATIENTS WILL HAVE LIFELONG ACCESS TO HIGH QUALITY, EFFECTIVE, AFFORDABLE AND COMPASSIONATE CARE. -- THE MOST ACCURATE CANCER INFORMATION WILL BE AVAILABLE SO THAT PATIENTS AND PHYSICIANS CAN MAKE INFORMED DECISIONS ABOUT CANCER PREVENTION AND TREATMENT. -- INFORMATION WE LEARN FROM EVERY PATIENT WILL BE USED TO ACCELERATE PROGRESS AGAINST CANCER. -- RESOURCES WILL EXIST TO ATTRACT THE BEST CLINICIANS AND INVESTIGATORS TO PROVIDE OPTIMAL PATIENT CARE AND TO CONDUCT TRANSFORMATIVE RESEARCH. --ASCO WILL BE RECOGNIZED AS THE MOST TRUSTED SOURCE OF CANCER INFORMATION WORLDWIDE. false false 37534203 1228824 52408575 EDUCATIONAL AND SCIENTIFIC MEETINGS AND PRODUCTS: ASCO PROVIDES EDUCATIONAL AND SCIENTIFIC PROGRAMS AND CONTENT ON A VARIETY OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON CUTTING EDGE RESEARCH AND SCIENCE IN THE FIELD OF CLINICAL ONCOLOGY. THE SCIENTIFIC RESEARCH AND EDUCATION PRESENTED AT THE MEETINGS ENHANCES KNOWLEDGE ABOUT CANCER, THUS ADVANCING HIGH-QUALITY CANCER CARE (SEE CONTINUATION ON SCH O). 13863508 124617 29319333 EDUCATIONAL PUBLICATIONS: ASCO PUBLISHES TWO EDUCATIONAL JOURNALS ADDRESSING CLINICAL ONCOLOGY THAT ARE AVAILABLE TO THE PUBLIC. JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS (SEE CONTINUATION ON SCH O). 10090708 18000 606701 QUALITY: THE ASCO QUALITY DEPARTMENT IS RESPONSIBLE FOR THE DEVELOPMENT OF EVIDENCE-BASED GUIDELINES, DEVELOPING AND VALIDATING QUALITY MEASURES IN ONCOLOGY, QUALITY IMPROVEMENT AND MEASUREMENT (SEE CONTINUATION ON SCH O). 12176430 529211 673890 73664849 true true false true false false false false false false true true false false true true false true false true true true true false false false false true false true true false false false false false false false false false false false false false false true true true true false false true 409 0 432 true true true false false false false false false false false false X 18 18 false false false false true true true true true false false true true true true true true true true false NY VA X ERIN HULTMAN CPA FINANCE D 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 Peter P Yu MD FASCO President 1.0 1.0 X X 0 0 0 Julie M Vose MD MBA FASCO President-elect 1.0 0.0 X X 0 0 0 Clifford A Hudis MD FACP Immediate Past President 1.0 0.0 X 0 0 0 Susan L Cohn MD Treasurer 1.0 0.0 X X 0 0 0 Smita Bhatia MD MPH Board Member 1.0 0.0 X 0 0 0 Charles D Blanke MD FACP FASCO Board Member 1.0 0.0 X 500 0 0 Linda D Bosserman MD FACP Board Member 1.0 0.0 X 0 0 0 Walter J Curran Jr MD FACR Board Member 1.0 0.0 X 0 0 0 Stephen S Grubbs MD Board Member 1.0 0.0 X 0 0 0 Paulo Hoff MD FACP Board Member 1.0 0.0 X 0 0 0 Hagop M Kantarjian MD Board Member 1.0 0.0 X 0 0 0 David Khayat MD PhD FASCO Board Member 1.0 0.0 X 0 0 0 Gary H Lyman MD MPH FASCO Board Member 1.0 0.0 X 0 0 0 Neal J Meropol MD FASCO Board Member 1.0 0.0 X 0 0 0 Therese M Mulvey MD FASCO Board Member 1.0 0.0 X 0 0 0 Carolyn D Runowicz MD FASCO Board Member 1.0 0.0 X 0 0 0 Lillian L Siu MD FRCPC Board Member 1.0 0.0 X 0 0 0 Eric P Winer MD FASCO Board Member 1.0 0.0 X 0 0 0 W Charles Penley MD FASCO CCF Chair (non-voting) 1.0 1.0 X 0 0 0 Allen S Lichter MD FASCO CEO/Ex-officio Dir(non-voting) 33.5 4.0 X X 810390 0 20730 Paul Aines CPA CFO 33.5 4.0 X 333500 0 36776 Dina Michels Esq VP, General CounseL, SECRETARY 33.5 4.0 X 492500 0 36416 Nancy Daly MS MPH Executive Director, CCF 1.0 36.5 X 259385 0 32795 Bernie Khoo SR. Dir Integrated Media 37.5 0.0 X 406500 0 36776 Deborah Kamin RN PHD Senior Director Cancer Policy 37.5 0.0 X 258000 0 35810 Jean Colvard sr dir Meeting Services 37.5 0.0 X 243000 0 25385 Kristin Ludwig Senior Director Communications 37.5 0.0 X 245000 0 19605 David Sampson Senior Director Journals 37.5 0.0 X 196300 0 27318 Jamie Von Roenn MD Senior Director Education 37.5 0.0 X 322500 0 36207 Richard Schilsky MD Chief Medical Officer 33.5 4.0 X 480000 0 32391 Suzanne Brach Senior Director Marketing 37.5 0.0 X 223000 0 30066 Douglas Pyle sr dir International affairs 37.5 0.0 X 207000 0 32207 Kay Noll sr dir Human Resources 37.5 0.0 X 212000 0 24035 MELISSA TAI SENIOR COUNSEL 37.5 0.0 X 220000 0 17044 4909575 0 443561 109 false true false THE CORKERY GROUP 260 Fifth Ave NEW YORK NY 10001 PUBLIC RELATIONS 1419640 THRUUE INC 235 Main Street Suite 227 MADISON NJ 07940 STRATEGY CONSULTING 1131277 MCDERMOTT WILL EMERY LLP PO BOX 6043 CHICAGO IL 60680 LEGAL 771192 ASTUTE TECHNOLOGY 11718 Bowmen Green Dr RESTON VA 20190 VIDEO RECORDING 583107 POLSINELLI SHUGHART PC 1152 15th St NW WASHINGTON DC 20005 LEGAL 522939 14 9545027 230028 77000 9852055 EDUCATION MEETINGS & PRODUCTS 900099 30110267 30110267 ADVERTISING 541800 16581342 665404 15915938 PUBLICATIONS 511190 13669711 13669711 MEMBERSHIP 900099 11751434 11751434 EXHIBITS 900099 10507700 10507700 388228 388228 83008682 3452574 3452574 0 1981795 1981795 921076 1472038 -550962 0 -550962 -550962 70006630 66308861 3697769 3697769 3697769 0 0 0 MAILING LIST 511120 386828 386828 TENANT PARKING 900099 99900 99900 486728 101928641 66704516 15853104 9518966 1316341 1316341 0 584311 584311 0 5208935 4656788 552147 0 22096050 18941993 3154057 1812851 1472035 340816 3032286 2462216 570070 2146246 1742752 403494 0 1227181 581851 645330 119299 88839 30460 171707 171707 0 639596 639596 12803768 11040204 1712765 50799 354227 327797 26430 1834453 1704593 129860 3105096 2111594 941325 52177 0 4468478 3063591 1198445 206442 3611569 3178778 422931 9860 0 8403592 7865620 486503 51469 0 0 2657391 2175669 246612 235110 429509 375077 30113 24319 PRINTING & PRODUCTION 6632488 6617643 8511 6334 DEVELOPMENT FEE TO CCF 2200000 2200000 POSTAGE & SHIPPING 1771615 1750128 21012 475 UBI TAX 1435322 1435322 88062311 73664849 11560477 2836985 300 300 4670425 5962166 0 0 4931658 5894637 0 0 0 0 0 0 0 0 2893602 3076387 67529013 15684250 54271682 51844763 113771697 119914888 14541834 21933705 0 0 0 0 513356 8912434 195594554 217539280 4603669 5304131 0 0 18956773 21067057 38400000 38400000 0 0 0 0 0 0 0 0 36311062 48038446 98271504 112809634 X 97323050 104729646 0 0 0 0 97323050 104729646 195594554 217539280 X 13866330 -975687 -5484047 X false true X true false X 8931139 7731584 9951001 8477875 9775055 44866654 70399472 72435660 73138765 76312383 83008682 375294962 0 0 0 79330611 80167244 83089766 84790258 92783737 420161616 12940190 10563934 13094217 11456835 12876427 60931603 0 12940190 10563934 13094217 11456835 12876427 60931603 359230013 944781 2794882 4333604 5333603 5821197 19228067 0 944781 2794882 4333604 5333603 5821197 19228067 1661960 2108381 3049601 3403799 3584676 13808417 0 81937352 85070507 90472971 93527660 102189610 453198100 0.79266 0.77030 0.04243 0.06510 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 10098 161609 171707 73493141 73664848 1000000 250000 1000000 1000000 1000000 1000000 4000000 6000000 148941 170099 170479 171707 661226 250000 250000 250000 250000 1000000 1500000 1320 12065 10098 23483 7342677 7342677 46631978 7799524 38832454 10784217 6419316 4364901 2770141 1465410 1304731 51844763 ALPHAKEYS DOUBLE BLACK DIAMOND 10425637 F UBS MILLENNIUM FUND (OFFSHORE) 11508068 F 21933705 0 LIABILITY UNDER INTEREST RATE SWAP AGREEMENT 16195109 TAXABLE BOND PAYABLE 24355000 DUE TO AFFILIATE 7488337 48038446 X 96224349 -975687 -5484047 -6459734 102684083 639596 -1395038 -755442 101928641 88894753 1472038 1472038 87422715 639596 639596 88062311 PART X, LINE 2 UNDER ASC TOPIC 740-10, ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, THE ORGANIZATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED AN EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE DECEMBER 31, 2010. PART XI, LINE 2D AND 4B - OTHER ADJUSTMENTS LINE 2D LOSS ON INTEREST RATE SWAP -5,484,047 LINE 4B RENTAL EXPENSES -1,472,038 CONTRIBUTION ELIMINATED ON RECONCILIATION 77,000 ---------- TOTAL LINE 4B ADJUSTMENTS -1,395,038 PART XII, LINE 2D - OTHER ADJUSTMENTS RENTAL EXPENSE 1,472,038 true East Asia and the Pacific Program Services OUTREACH & EDUCATIONAL 69132 Europe (Including Iceland and Greenland) Program Services OUTREACH & EDUCATIONAL 98045 Middle East and North Africa Program Services OUTREACH & EDUCATIONAL 69400 North America 3 Program Services OUTREACH & EDUCATIONAL 25877 Russia and the Newly Independent States Program Services OUTREACH & EDUCATIONAL 68919 South America Program Services OUTREACH & EDUCATIONAL 32768 South Asia Program Services OUTREACH & EDUCATIONAL 87583 Sub-Saharan Africa Program Services OUTREACH & EDUCATIONAL 77487 Central America and the Caribbean Investments 18873236 3 3 19402447 19402447 Europe (Including Iceland and Greenland) Support of 10 UICC ICRETT fellows 40800 CHECK Europe (Including Iceland and Greenland) Support for 3 Flims Workshop attendees in 2013 14300 CHECK 2 IDEA award East Asia and the Pacific 4 4720 CASH/CHECK 17573 TRAVEL BOOK IDEA award Europe (Including Iceland and Greenland) 2 2520 CASH/CHECK 8104 TRAVEL BOOK IDEA award North America 2 2200 CASH/CHECK 6144 TRAVEL BOOK IDEA award Russia and the Newly Independent States 4 5040 CASH/CHECK 17184 TRAVEL BOOK IDEA award South America 2 2200 CASH/CHECK 8367 TRAVEL BOOK IDEA award South Asia 5 5500 CASH/CHECK 22743 TRAVEL BOOK IDEA award Sub-Saharan Africa 5 6140 CASH/CHECK 18847 TRAVEL BOOK true false false false false false SCHEDULE F, PART I, LINE 1 INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS PROVIDE SUPPORT FOR EARLY-CAREER ONCOLOGISTS IN DEVELOPING COUNTRIES TO LEARN ABOUT ONCOLOGY CARE AND RESEARCH BY ESTABLISHING STRONG RELATIONSHIPS WITH LEADING ASCO ONCOLOGISTS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. RECIPIENTS LEARN ABOUT QUALITY CANCER CARE AND RESEARCH BY ATTENDING THE ASCO ANNUAL MEETING AND VISITING THEIR MENTOR'S CANCER CENTER IN THE UNITED STATES AND CANADA. RECIPIENTS ARE EXPECTED TO SHARE THE KNOWLEDGE AND TRAINING THEY RECEIVE THROUGH THE PROGRAM WITH COLLEAGUES IN THEIR HOME COUNTRIES ONCE THEY RETURN. IDEAS ARE PROVIDED TO RECIPIENTS BASED ON MERIT THROUGH A PEER REVIEW PROCESS USING ESTABLISHED ELIGIBILITY CRITERIA. IDEA RECIPIENTS ARE REQUIRED TO AGREE TO TERMS AND CONDITIONS APPLICABLE TO THE IDEA, ARE REQUIRED TO COMMUNICATE WITH THEIR MENTORS, TO ATTEND ALL IDEA-RELATED EVENTS, TO SUBMIT EVALUATIONS AFTER THE ANNUAL MEETING AND MENTOR SITE VISIT, AND TO SUBMIT ONE-YEAR REPORTS. true Komen National Race for the Cure 1911 N Fort Myer Drive 112 Arlington VA 22209 751835298 501 (c) (3) 25000 Contribution ORGANIZATION) Friends of Cancer Research 3299 K Street NW Washington DC 20007 521983273 501 (c) (3) 20000 Contribution National Coalition for Cancer Survivorship 1010 Wayne Avenue 770 Silver Spring MD 20910 850357897 501 (c) (3) 10000 Contribution American College of Surgeons 633 North St Clair Chicago IL 60611 362192800 501 (c) (3) 50000 Contribution National Academy of Sciences 2101 Constitution Avenue NW Washington DC 20418 530196932 501 (c) (3) 16500 Contribution Brookings Institution 1775 Massachusetts Ave Washington DC 20036 530196577 501 (c) (3) 10000 Contribution Conquer Cancer Foundation 2318 Mill Rd Ste 800 Alexandria VA 22314 311667995 501 (c) (3) 740000 Contribution American Association for Cancer Research 615 Chestnut St 17th Floor Philadelphia PA 19106 236251648 501 (c) (3) 10000 Contribution Duke University Medical Center 2424 Erwin Rd Suite 601 Durham NC 27705 560532129 501 (c) (3) 25000 Contribution University of Chicago 1427 E 60th St Suite 120 Chicago IL 60637 362177139 501 (c) (3) 49802 Contribution Palo Alto Medical Foundation 795 El Camino Rd Palo Alto CA 94301 941156581 501 (c) (3) 151049 Contribution Memorial Sloan Ketting Institute PO Box 026338 New York NY 10087 131924236 501 (c) (3) 95873 Contribution Washington Cancer Institute 110 Irving St NW Washington DC 20010 521272129 501 (c) (3) 10139 Contribution Health Volunteers Overseas 1900 L St NW 310 Washington DC 20036 521485477 501 (c) (3) 10000 Contribution Breast Cancer Research Foundation 60 East 56th Street 8th Floor New York NY 10022 133727250 501 (c) (3) 40000 Contribution University of Nebraska Medical Center 985520 Nebraska Medical Center Omaha NE 68198 911858433 501 (c) (3) 47978 Contribution 16 SCHEDULE I, PART I, LINE 1 ASCO provides assistance to 501c3 organizations that serve the cancer community. X true true X X X X X X false false false true true false false true true true Allen S Lichter MD FASCO CEO/Ex-officio Dir(non-voting) 671390 0 79000 0 60000 0 19500 0 1230 0 831120 0 0 0 Richard Schilsky MD Chief Medical Officer 465000 0 15000 0 0 0 19500 0 12891 0 512391 0 0 0 Paul Aines CPA CFO 321500 0 12000 0 0 0 19500 0 17276 0 370276 0 0 0 Dina Michels Esq VP, General CounseL, SECRETARY 492500 0 0 0 0 0 19500 0 16916 0 528916 0 0 0 Nancy Daly MS MPH Executive Director, CCF 249385 0 10000 0 0 0 19454 0 13341 0 292180 0 0 0 Bernie Khoo SR. Dir Integrated Media 365500 0 41000 0 0 0 19500 0 17276 0 443276 0 0 0 Deborah Kamin RN PHD Senior Director Cancer Policy 248000 0 10000 0 0 0 19350 0 16460 0 293810 0 0 0 Jean Colvard sr dir Meeting Services 234000 0 9000 0 0 0 18225 0 7160 0 268385 0 0 0 Kristin Ludwig Senior Director Communications 236000 0 9000 0 0 0 18375 0 1230 0 264605 0 0 0 Suzanne Brach Senior Director Marketing 214500 0 8500 0 0 0 16725 0 13341 0 253066 0 0 0 Douglas Pyle sr dir International affairs 200000 0 7000 0 0 0 15525 0 16682 0 239207 0 0 0 Kay Noll sr dir Human Resources 204000 0 8000 0 0 0 15900 0 8135 0 236035 0 0 0 David Sampson Senior Director Journals 194300 0 2000 0 0 0 14662 0 12656 0 223618 0 0 0 Jamie Von Roenn MD Senior Director Education 300000 0 22500 0 0 0 19500 0 16707 0 358707 0 0 0 MELISSA TAI SENIOR COUNSEL 220000 0 0 0 0 0 16500 0 544 0 237044 0 PART I, LINE 1A A housing allowance is provided to the CEO, which is considered part of the CEO's compensation and addressed in the CEO's written employment contract. The allowance is treated as taxable compensation. PART I, LINE 5A & 5B PERFORMANCE-BASED BONUS PAYMENTS CAN BE MADE TO SOME EMPLOYEES LISTED ON SCHEDULE J AND INCLUDED AS PART OF THE TOTAL COMPENSATION. THE BONUS PAYMENTS ARE NOT ON A FIXED BASIS BUT RATHER ARE BASED ON PERFORMANCE AND DETERMINED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. PART I, LINE 8 Certain amounts paid or accrued to the CEO and the VP/GC were pursuant to contracts that were subject to the initial contract exception described in Treasury Regulation Section 53 4958-4(A)(3). A INDUSTRIAL DEVELOPMENT AUTHORITYCITY OF ALEXANDRI 521381432 01530LAD2 2012-08-01 38400000 Buy/Buildout 5 floors HQ building false false false A 0 0 38400000 0 0 0 0 0 0 38400000 0 0 2008 false false true true A false false true true false 0.00000 0.00500 0.00500 false false false true A false false false false true true FMS WENTWORTH 30. false false false 0 false true A true PART IV, QUESTION 3 ASCO has an interest rate swap agreement with FMS Wentworth Bank through 2038. ASCO makes fixed interest payments at a 3.587% rate. Variable swap payments, based on one-month LIBOR, received from the swap counterparty are used to make the variable interest payments as they come due. These interest rate swap agreements qualify as a derivative instrument and are used to mitigate the effect of interest rate fluctuations. FORM 990, PART III, LINE 4D CANCER POLICY AND CLINICAL AFFAIRS: ASCO'S CANCER POLICY AND CLINICAL AFFAIRS DEPARTMENT ADDRESSES POLICY ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, CANCER RESEARCH, CARE AND PREVENTION. THE DEPARTMENT WORKS WITH VOLUNTEER COMMITTEES AND ASCO LEADERS TO SHAPE POLICY, LAW AND REGULATION ON ISSUES OF IMPORTANCE IN ONCOLOGY. THE DEPARTMENT'S PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING PATIENT-ORIENTED RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ACTIVITIES INCLUDE HOTLINES, TOOLS, EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. CANCER POLICY AND CLINICAL AFFAIRS STAFF INTERACT AND COLLABORATE ON A REGULAR BASIS WITH ASCO STATE AND REGIONAL AFFILIATES, OTHER MEDICAL SPECIALTY AND PROFESSIONAL SOCIETIES, CONGRESS, THE ADMINISTRATION, AND PATIENT ADVOCATE ORGANIZATIONS TO ADVANCE COMMON GOALS RELATED TO CANCER RESEARCH AND QUALITY CARE. THE STATE/REGIONAL AFFILIATE PROGRAM: THE AFFILIATE PROGRAM WAS CREATED IN 1993 TO BETTER ADDRESS ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, AND TO FACILITATE ASCO'S OWN ADVOCACY PROGRAMS. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. FEDERAL POLICIES IMPACTING CANCER CARE AND RESEARCH: ASCO REVIEWS AND FREQUENTLY COMMENTS ON POLICIES ISSUED BY FEDERAL AGENCIES, INCLUDING THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS), FOOD AND DRUG ADMINISTRATION (FDA), AND NATIONAL INSTITUTES OF HEALTH (NIH). STAFF AND VOLUNTEERS ALSO ACTIVELY PARTICIPATE IN AMERICAN MEDICAL ASSOCIATION (AMA) PROCESSES FOR DEVELOPMENT OF NEW CPT CODES AND VALUATION OF CODES THROUGH THE AMA/SPECIALTY SOCIETY RELATIVE VALUE SCALE UPDATE COMMITTEE (RUC). MEMBER RELATIONS AND INFORMATION: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 34,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS. ASCO CONNECTION IS THE OFFICIAL BIMONTHLY MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO. IT IS THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CUTTING EDGE RESEARCH, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE. COMMUNICATIONS AND PATIENT INFORMATION: ASCO PROVIDES THE PUBLIC, INCLUDING PATIENTS, THE MEDIA, LEGISLATORS, PHYSICIANS AND OTHER HEALTH CARE PROFESSIONALS, WITH ACCURATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. ASCO HAS A FREE PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), AVAILABLE TO THE PUBLIC, INCLUDING PATIENTS, THEIR CAREGIVERS, FAMILY MEMBERS AND FRIENDS, THE MEDIA AND HEALTH CARE PROFESSIONALS, THAT PROVIDES UP-TO-DATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. THE SITE OFFERS MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER. IN ADDITION TO ITS WEBSITE CONTENT, ASCO OFFERS PRINTED MATERIALS FOR PATIENTS, SUCH AS: CANCER.NET'S GUIDES TO CANCER (DETAILED GUIDES COVERING SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT,CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR), ASCO ANSWERS FACT SHEETS (A SERIES OF FACT SHEETS THAT PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, QUESTIONS TO ASK THE DOCTOR), BOOKLETS ON TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. ADDITIONAL RESOURCES AVAILABLE ON CANCER.NET. ASCO ALSO PROVIDES THE FOLLOWING INFORMATIONAL SERVICES TO THE PUBLIC: FIND AN ONCOLOGIST DATABASE: A FREE SEARCHABLE DATABASE OF ASCO MEMBERS BY SPECIALTY OR LOCATION FOR THOSE IN NEED OF A SPECIALIST. CANCER ADVANCES: SUMMARIES OF RESEARCH ADVANCES IN CLINICAL ONCOLOGY FROM THE JOURNAL OF CLINICAL ONCOLOGY, ASCO'S ANNUAL MEETINGS, AND ASCO SYMPOSIA. WHAT TO KNOW: ASCO'S GUIDELINES: PATIENT-FRIENDLY GUIDES BASED ON ASCO'S CLINICAL PRACTICE GUIDELINES FOR PHYSICIANS. RESEARCH AND MEETINGS: INFORMATION ON ASCO'S ANNUAL MEETINGS AND SYMPOSIA, VIRTUAL LECTURES, AND ASCO'S EXPERT PERSPECTIVE ON CANCER NEWS. MULTIMEDIA: MEDICAL ILLUSTRATIONS, MOBILE APP, VIDEOS, AND PODCASTS ON TOPICS SUCH AS: CANCER RESEARCH, TREATMENT, AND COPING. EXPERT INFORMATION FROM ASCO: ASCO EXPERTS ANSWER QUESTIONS ABOUT CURRENT TOPICS IN CANCER CARE, TREATMENT, AND RESEARCH. CANCER.NET FEATURE ARTICLES: WEEKLY ARTICLES DESIGNED TO PROVIDE IN-DEPTH INFORMATION ON TOPICS OF INTEREST, AS WELL AS PRACTICAL INFORMATION ON CANCER CARE AND TREATMENT. ASCO CANCER TREATMENT SUMMARY FORMS: PRINTABLE FORMS PATIENTS AND THEIR DOCTORS CAN COMPLETE TO HELP KEEP TRACK OF TREATMENT PLANS AND FOLLOW-UP CARE PLANS. CANCER.NET EN ESPANOL: TRANSLATED CONTENT ON THE TREATMENT OF COMMON CANCER TYPES, MANAGING SIDE EFFECTS, AN INTRODUCTION TO CLINICAL TRIALS, SURVIVORSHIP, AND ASCO'S GUIDELINES. SEVERAL PRINTED PIECES ARE ALSO AVAILABLE IN SPANISH. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2014, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, TREASURER, IMMEDIATE PAST-PRESIDENT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. NO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCOS PROFITS OR EXCESS DUES OR A SHARE OF ASCOS NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP WITH VOTING RIGHTS AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. 2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 65, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. 2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 3. HONORARY MEMBERS. 3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. 3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION A, LINE 7B ASCOS CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE VICE PRESIDENT AND GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C CCF MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CCF STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CCF'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED WHEN ANY MATERIAL CHANGES OCCUR. IN ADDITION, CCF OFFICERS, DIRECTORS, AND KEY EMPLOYEES ARE REQUIRED TO DISCLOSE ANNUALLY BUSINESS RELATIONSHIPS OR ANY TRANSACTIONS THEY OR THEIR RELATED ENTITIES OR FAMILY MEMBERS HAVE WITH CCF OR WITH OTHER OFFICERS, DIRECTORS OR KEY EMPLOYEES. CCF'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CCF IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CCF DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF); THE PRESIDENT OF ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM AND D/B/A CANCERLINQ); THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF DIRECTORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. VICE PRESIDENT/GENERAL COUNSEL: THE COMPENSATION OF THE VICE PRESIDENT/GENERAL COUNSEL (VP/GC) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE VP/GC WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE VP/GC AND ASCO ADDRESSES COMPENSATION OF THE VP/GC. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP/GC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. CHIEF FINANCIAL OFFICER (CFO). THE COMPENSATION OF THE CHIEF FINANCIAL OFFICER (CFO) WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE CFO WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. EXECUTIVE DIRECTOR OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CCF): THE EXECUTIVE DIRECTOR OF CCF IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED AND APPROVED THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EXECUTIVE DIRECTOR OF CCF BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY: THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS CONSIDERED AND APPROVED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SENIOR DIRECTOR, INTEGRATED MEDIA AND TECHNOLOGY BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2014. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE, AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART XI, LINE 9 LOSS ON INTEREST RATE SWAP -5,484,047 FORM 990, PART III, LINE 4A CONTINUATION OF PROGRAM SERVICE ACCOMPLISHMENT: THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER EDUCATIONAL AND SCIENTIFIC MEETING IN THE ONCOLOGY COMMUNITY AND THE THEMATIC MEETINGS PRESENTED OR CO-SPONSORED BY ASCO PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC PROGRAMMING ON SPECIFIC TYPES OF CANCERS. ASCO'S EDUCATIONAL AND SCIENTIFIC PROGRAMS SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE AND ASSIST THEM IN PROVIDING WORLD CLASS CANCER CARE AND IN CONDUCTING CUTTING EDGE RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. APPROPRIATE PROGRAMS ARE PROVIDED FOR ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, AND OTHERS TO MEET THE CHANGING NEEDS OF PEOPLE LIVING WITH CANCER AND ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS SO THAT THEY ARE BETTER PREPARED TO MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY,ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM. ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT AVAILABLE TO THE GENERAL PUBLIC THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES EDUCATIONAL AND SCIENTIFIC MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2014 ACTIVITIES INCLUDE: OVER 34,000 PEOPLE ATTENDED THE 2014 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES,CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. MORE THAN HALF OF ATTENDEES AT THE 2014 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2014 ANNUAL MEETING FEATURED OVER 220 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 4,500 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 3,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY. IN ADDITION TO THE ASCO ANNUAL MEETING, ASCO SPONSORED OR CO-SPONSORED OVER 50 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE IN AND AROUND THE WORLD. THESE MEETINGS INCLUDED: - BEST OF ASCO CENTRAL - BEST OF ASCO EASTERN - BEST OF ASCO WESTERN - PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM - ASCO'S QUALITY CARE SYMPOSIUM - GI CANCERS SYMPOSIUM - GU CANCERS SYMPOSIUM - BREAST CANCER SYMPOSIUM - ASCO/AACR METHODS WORKSHOP INTERNATIONAL AFFAIRS MEETINGS AND COURSES: - BEST OF ASCO INTERNATIONAL (24) - JOINT SYMPOSIA (16) - ADVANCED CANCER COURSES (8) - MULTIDISCIPLINARY CANCER MANAGEMENT COURSES (4) ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR LIVE MEETINGS. THE DAILY NEWS PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AT THE LIVE EVENT AND ONLINE (THE ENTIRETY OF THE PRINT VERSIONS PLUS BONUS COVERAGE) TO ASCO MEMBERS AND TO THE GENERAL PUBLIC. THE DAILY NEWS PRODUCTS INCLUDE COVERAGE OF KEY EDUCATIONAL AND SCIENTIFIC SESSIONS, EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. FORM 990, PART III, LINE 4B CONTINUATION OF PROGRAM SERVICE ACCOMPLISHMENT: THE JOURNALS INCLUDE ORIGINAL REPORTS, SELECTED EDITORIALS, COMMENTARIES, REVIEWS, AND OTHER WORK THAT RELATES TO THE CARE OF PATIENTS WITH CANCER. JCO IS TRANSLATED INTO A NUMBER OF LANGUAGES IN INTERNATIONAL EDITIONS, THERBY INCREASING ITS USE INTERNATIONALLY. IN 2014 JOURNAL OF CLINICAL ONCOLOGY HAD OVER 26,000 ANNUAL SUBSCRIBERS. ADDITIONALLY, AS REPORTED BY THOMSON REUTERS IN ITS 2013 JOURNAL CITATION REPORT, JCO'S IMPACT FACTOR OF 17.960 RANKED IT #53 OUT OF 8,336 JOURNALS MEASURED AND #5 IN THE ONCOLOGY CATEGORY (196 JOURNALS MEASURED). JCO RECEIVED 120,262 TOTAL CITATIONS IN 2011, WHICH RANKED IT #23 OVERALL AND #2 IN THE ONCOLOGY CATEGORY. JCO'S EIGENFACTOR SCORE OF 0.39463 (A MEASURE OF WHAT TYPES OF CITATIONS WERE GENERATED) RANKED IT #16 OVERALL AND #1 IN THE ONCOLOGY CATEGORY. THE IMPACT FACTOR, TOTAL CITATIONS, AND EIGENFACTOR SCORES ARE ALL REFLECTIONS OF THE VALUE RESEARCHERS FIND IN JCO CONTENT. IN 2013, JOURNAL OF ONCOLOGY PRACTICE (JOP) WAS ACCEPTED FOR INDEXING IN MEDLINE, THE PREMIER BIBLIOGRAPHIC DATABASE OF THE U.S. NATIONAL LIBRARY OF MEDICINE (NLM). THE INCLUSION OF JOP IN MEDLINE GIVES AN INDICATION OF ITS GROWING PROMINENCE AND REPUTATION IN ONCOLOGY AND IS A REFLECTION OF THE VERY HIGH QUALITY OF ITS PUBLISHED ARTICLES. FORM 990, PART III, LINE 4C CONTINUATION OF PROGRAM SERVICE ACCOMPLISHMENT: PROGRAMS INCLUDE: - CANCERLINQ, AN INITIATIVE TO DEVELOP A RAPID LEARNING SYSTEM IN ONCOLOGY. THIS EFFORT IS INTENDED TO TRANSFORM THE WAY ONCOLOGISTS PRACTICE, LEARN, AND INTERACT WITH THEIR PATIENTS. FOLLOWING THE PRESENTATION OF A SUCCESSFUL PROOF-OF-CONCEPT PROTOTYPE IN 2013, ASCO FORMALLY INITIATED DEVELOPMENT OF THE FULL CANCERLINQ SYSTEM. - QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. THE PROGRAM IS UNIQUE IN THE CANCER COMMUNITY AND HAS BEEN ACCEPTED BY THE AMERICAN BOARD OF INTERNAL MEDICINE AS A MECHANISM FOR SATISFYING PRACTICE EVALUATION AND IMPROVEMENT REQUIREMENTS FOR MAINTENANCE OF CERTIFICATION. ASCO SUPPORTS A NUMBER OF COLLABORATIVE GROUPS THAT USE QOPI WITHIN THEIR INITIATIVES TO DRIVE THEIR QUALITY IMPROVEMENT EFFORTS. OVER 700 PRACTICES NATIONWIDE, INCLUDING PRACTICES IN HAWAII, ALASKA, GUAM, AND PUERTO RICO, ARE ENROLLED IN THE PROGRAM. - QOPI CERTIFICATION PROGRAM. THE QOPI CERTIFICATION PROGRAM BUILDS UPON THE SUCCESS OF QOPI. QOPI CERTIFICATION DEMONSTRATES A COMMITMENT TO EXCELLENCE AND ONGOING QUALITY IMPROVEMENT IN THE HEMATOLOGY-ONCOLOGY OUTPATIENT PRACTICE. THE GOALS OF THE QOPI CERTIFICATION PROGRAM ARE TO: - PROMOTE HIGH QUALITY CANCER CARE AS DEFINED BY THE CLINICIAN EXPERTS. - PROVIDE A TRUSTED SOLUTION TO SATISFY EXTERNAL DEMAND FOR QUALITY ACTIVITIES. - REDUCE REDUNDANT PROGRAMS OR ADMINISTRATIVE BURDENS RELATED TO THE DEMONSTRATION OF QUALITY. THE QOPI CERTIFICATION PROGRAM IS CARRIED OUT BY A SPECIAL-PURPOSE LIMITED LIABILITY CORPORATION (LLC), ASCO INSTITUTE FOR QUALITY, LLC (D/B/A QOPI CERTIFICATION PROGRAM). THE SOLE MEMBER OF THIS LLC IS ASCO AND THE PRESIDENT IS ASCO'S CHIEF EXECUTIVE OFFICER. - NEW GUIDELINES AND ONGOING UPDATES. ASCO HAS PUBLISHED OVER 50 PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. FORM 990 PART IX LINE 11G DESCRIPTION:COMMISSIONS TOTAL FEES:2930500 FORM 990 PART IX LINE 11G DESCRIPTION:PUBLIC RELATIONS COORDINATOR TOTAL FEES:1440146 FORM 990 PART IX LINE 11G DESCRIPTION:OTHER PROFESSIONAL SERVICES TOTAL FEES:8433122 ASCO INSTITUTE FOR QUALITY LLC 2318 MILL ROAD ALEXANDRIA VA 22314 271629211 QOPI CERT PRO VA 388228 1227928 ASCO ASCO LEASING LLC 2318 MILL ROAD ALEXANDRIA VA 22314 273378225 RENTAL VA 1020976 130892 ASCO CANCERLINQ LLC 2318 MILL ROAD ALEXANDRIA VA 22314 472315885 QUALITY IMPRO VA 2900000 2023951 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL ROAD ALEXANDRIA VA 22314 311667995 Grants VA 501C3 509(A)(1) true true true true false true false false false false true false false true true true true true false false